| 3,392 | 46 | 83 |
| 下载次数 | 被引频次 | 阅读次数 |
胰岛素抵抗(IR)在多囊卵巢综合征(PCOS)的诊治中愈发受到重视。然而，目前国内外对于PCOS患者合并IR的诊断和治疗尚无统一共识。因此，本文参考最新国际指南和共识，结合中国临床实践，经充分讨论后形成该共识，旨在为PCOS合并IR患者的诊治提供相关指导和建议，以提升临床诊治水平，改善患者预后。这一共识的形成可弥补目前该领域的知识空缺，为医务人员提供科学和实用的依据，进而更好地应对PCOS合并IR的临床挑战。
Abstract：Insulin resistance(IR) is increasingly recognized as a crucial aspect in the diagnosis and management of polycystic ovary syndrome(PCOS). However, a global consensus on standardized procedures for addressing IR in PCOS is currently lacking.This article seeks to fill this gap by drawing on the latest international guidelines and consensus, alongside insights from contemporary clinical practices in China. Through comprehensive discussions, this consensus is formulated with the aim of providing relevant guidance for diagnosis and treatment of PCOS in conjunction with IR. The ultimate objective is to elevate diagnostic and treatment standards and enhance patient prognosis. This consensus aspires to contribute to the field by bridging existing knowledge gaps, empowering medical professionals with a scientifically grounded and practical framework to effectively navigate the clinical challenges presented by PCOS combined with IR.
[1] Azziz R,Carmina E,Chen Z,et al.Polycystic ovary syndrome[J].Nat Rev Dis Primers,2016,2:16057.
[2] Visser JA.The importance of metabolic dysfunction in polycystic ovary syndrome[J].Nat Rev Endocrinol,2021,17:77-78.
[3] Zhao H,Zhang J,Cheng X,et al.Insulin resistance in polycystic ovary syndrome across various tissues:an updated review of pathogenesis,evaluation,and treatment[J].J Ovarian Res,2023,16:9.
[4] Li W,Chen Q,Xie Y,et al.Prevalence and degree of insulin resistance in Chinese Han women with PCOS:Results from euglycemic-hyperinsulinemic clamps[J].Clin Endocrinol(Oxf),2019,90:138-144.
[5] Teede HJ,Tay CT,Laven JJE,et al.Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J].Eur J Endocrinol,2023,189:G43-G64.
[6] Fauser BC,Tarlatzis BC,Rebar RW,et al.Consensus on women’s health aspects of polycystic ovary syndrome(PCOS):the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group[J].Fertil Steril,2012,97:28-38.e25.
[7] 齐家，孙赟，陈子江.多囊卵巢综合征子宫内膜胰岛素抵抗的分子机制及生物学效应[J].中华生殖与避孕杂志，2018,38:513-516.
[8] 厉心愉，孙贇.多囊卵巢综合征患者卵巢局部胰岛素抵抗研究进展[J].中华生殖与避孕杂志，2020,40:819-822.
[9] McCartney CR,Campbell RE.Abnormal GnRH pulsatility in polycystic ovary syndrome:recent insights[J].Curr Opin Endocr Metab Res,2020,12:78-84.
[10] Zhu JL,Chen Z,Feng WJ,et al.Sex hormone-binding globulin and polycystic ovary syndrome[J].Clin Chim Acta,2019,499:142-148.
[11] Li M,Chi X,Wang Y,et al.Trends in insulin resistance:insights into mechanisms and therapeutic strategy[J].Signal Transduct Target Ther,2022,7:216.
[12] Dumesic DA,Padmanabhan V,Abbott DH.Polycystic ovary syndrome and oocyte developmental competence[J].Obstet Gynecol Surv,2008,63:39-48.
[13] Siddiqui S,Mateen S,Ahmad R,et al.A brief insight into the etiology,genetics,and immunology of polycystic ovarian syndrome(PCOS)[J].J Assist Reprod Genet,2022,39:2439-2473.
[14] He FF,Li YM.Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome:a review[J].J Ovarian Res,2020,13:73.
[15] 多囊卵巢综合征相关不孕治疗及生育保护共识专家组，中华预防医学会生育力保护分会生殖内分泌生育保护学组.多囊卵巢综合征相关不孕治疗及生育保护共识[J].生殖医学杂志，2020,29:843-851.
[16] Zhao X,An X,Yang C,et al.The crucial role and mechanism of insulin resistance in metabolic disease[J].Front Endocrinol(Lausanne),2023,14:1149239.
[17] Bhattacharya SM,Jha A.Prevalence and risk of depressive disorders in women with polycystic ovary syndrome(PCOS)[J].Fertil Steril,2010,94:357-359.
[18] Pomytkin IA,Cline BH,Anthony DC,et al.Endotoxaemia resulting from decreased serotonin tranporter(5-HTT) function:a reciprocal risk factor for depression and insulin resistance?[J].Behav Brain Res,2015,276:111-117.
[19] Gluvic Z,Zaric B,Resanovic I,et al.Link between metabolic syndrome and insulin resistance[J].Curr Vasc Pharmacol,2017,15:30-39.
[20] Ogawa W,Araki E,Ishigaki Y,et al.New classification and diagnostic criteria for insulin resistance syndrome[J].Diabetol Int,2022,13:337-343.
[21] 中华医学会糖尿病学分会.胰岛素抵抗相关临床问题专家共识(2022版)[J].中华糖尿病杂志，2022,14:1368-1379.
[22] 中国医师协会内分泌代谢科医师分会.多囊卵巢综合征诊治内分泌专家共识[J].中华内分泌代谢杂志 2018,34:1-7.
[23] 唐玉珠，苏椿淋，王经纬，等.基于人体成分测定进行互联网线上生活方式干预在多囊卵巢综合征患者治疗中作用的多中心前瞻性研究[J].中华生殖与避孕杂志，2019,39:177-184.
[24] Teede HJ,Misso ML,Costello MF,et al.Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J].Hum Reprod,2018,33:1602-1618.
[25] Jiskoot G,Timman R,Beerthuizen A,et al.Weight reduction through a cognitive behavioral therapy lifestyle intervention in PCOS:the primary outcome of a randomized controlled trial[J].Obesity,2020,28:2134-2141.
[26] 林金芳.关于多囊卵巢综合征患者的生活方式干预[J].中华生殖与避孕杂志，2019,39:173-176.
[27] Graff SK,Mario FM,Ziegelmann P,et al.Effects of orlistat vs.metformin on weight loss-related clinical variables in women with PCOS:systematic review and meta-analysis[J].Int J Clin Pract,2016,70:450-461.
[28] 邢建东，姚艳琴，李鸿斌，等.贝那鲁肽联合二甲双胍治疗2型糖尿病合并多囊卵巢综合征肥胖患者疗效观察[J].中国药物与临床，2021,21:2484-2485.
[29] Szczesnowicz A,Szeliga A,Niwczyk O,et al.Do GLP-1 analogs have a place in the treatment of PCOS?New insights and promising therapies[J].J Clin Med,2023,12:5915.
[30] 苏椿淋，唐玉珠，林金芳.基于人体成分分析的生活方式干预在非肥胖型多囊卵巢综合征患者治疗作用的初步研究[J].中华生殖与避孕杂志，2020,40:716-722.
[31] McBreairty LE,Chilibeck PD,Gordon JJ,et al.Polycystic ovary syndrome is a risk factor for sarcopenic obesity:a case control study[J].BMC Endocr Disord,2019,19:70.
[32] Domin R,Dadej D,Pytka M,et al.Effect of various exercise regimens on selected exercise-induced cytokines in healthy people[J].Int J Environ Res Public Health,2021,18:1261.
[33] Yang R,Li Q,Zhou Z,et al.Changes in the prevalence of polycystic ovary syndrome in China over the past decade[J].Lancet Reg Health West Pac,2022,25:100494.
[34] 中华医学会妇产科学分会妇科内分泌学组.排卵障碍性异常子宫出血诊治指南[J].中华妇产科杂志，2018,53:801-807.
[35] Puurunen J,Piltonen T,Morin-Papunen L,et al.Unfavorable hormonal,metabolic,and inflammatory alterations persist after menopause in women with PCOS[J].J Clin Endocrinol Metab,2011,96:1827-1834.
[36] Wei D,Shi Y,Li J,et al.Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome[J].Hum Reprod,2017,32:354-361.
[37] 《二甲双胍临床应用专家共识》更新专家组.二甲双胍临床应用专家共识(2023年版)[J].中华内科杂志，2023,62:619-630.
[38] Xu Y,Wu Y,Huang Q.Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis[J].Arch Gynecol Obstet,2017,296:661-677.
[39] Valsamakis G,Lois K,Kumar S,et al.Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome(PCOS)[J].Hormones(Athens),2013,12:363-378.
[40] Zhang YY,Hou LQ,Zhao TY.Effects of acarbose on polycystic ovary syndrome:a meta-analysis[J].Exp Clin Endocrinol Diabetes,2014,122:373-378.
[41] Zeng L,Yang K.Effectiveness of myoinositol for polycystic ovary syndrome:a systematic review and meta-analysis[J].Endocrine,2018,59:30-38.
[42] 瞿睿，王璟萱，李赛姣.小檗碱在多囊卵巢综合征治疗中的研究进展[J].中华生殖与避孕杂志，2023,43:316-320.
基本信息:
中图分类号:R711.75
引用信息:
[1].多囊卵巢综合征合并胰岛素抵抗诊治专家共识[J].生殖医学杂志,2024,33(09):1133-1140.
2024-09-15
2024-09-15